NRAS and colorectal carcinoma: This phenomenon makes RAS-mutated CRC cells resistant to anti-EGFR monoclonal antibody-based treatments (cetuximab or panitumumab), so their use is recommended by the EMA (European Medical Agency) and FDA (Food and Drug Administration) only in mCRC patients with wild-type (wt) KRAS and NRAS.